Hypercoagulability in Cushing's syndrome: From arterial to venous disease

被引：15

作者：

St-Jean, Matthieu ^{[1
]}

Lim, Dawn S. T. ^{[2
]}

Langlois, Fabienne ^{[1
]}

机构：

[1] Ctr Hosp Univ Sherbrooke, Dept Med, Div Endocrinol, Ctr Integre Univ Sante & Serv Sociaux Estrie, Sherbrooke, PQ, Canada

[2] Singapore Gen Hosp, Dept Endocrinol, Singapore, Singapore

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2021年 / 35卷 / 02期

关键词：

venous thromboembolism; Cushing disease; Cushing syndrome; hypercoagulability; anticoagulation; cardiovascular disease; VON-WILLEBRAND-FACTOR; CARDIOVASCULAR RISK; ADRENAL INCIDENTALOMAS; THROMBOEMBOLISM; PROPHYLAXIS; STATE; HYPERCORTISOLISM; GLUCOCORTICOIDS; MANAGEMENT; MORTALITY;

D O I：

10.1016/j.beem.2021.101496

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cushing's syndrome (CS) is associated with multisystemic complications; the hematological system is not spared. Alteration in hemostatic parameters and in vivo endothelial dysfunction lead to increased thrombotic events. Arterial and venous thrombotic events carry significant morbidity and mortality. Death from cardiovascular and pulmonary embolism account for more than 50% of mortality. Surgery is a critical period; close to 50% of events occur in the 1-2 months after intervention. The evaluation and risk stratification of patients with CS is key to prevent events, balancing the risk-benefit of anticoagulation in this population. This current review will focus on up-to-date data on epidemiology, pathophysiology and management of hypercoagulability in CS. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页数：17